Next Article in Journal
Detection of the Potential Inactivation of Tetrodotoxin by Lactic Acid Bacterial Exopolysaccharide
Next Article in Special Issue
The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders
Previous Article in Journal
Synergistic Effects of Influenza and Staphylococcus aureus Toxins on Inflammation Activation and Cytotoxicity in Human Monocytic Cell Lines
Previous Article in Special Issue
Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)

Gut Microbiota and Cardiovascular Uremic Toxicities

Division of Renal Diseases and Hypertension, The George Washington University, Washington, DC 20037, USA
Department of Medicine, Georgetown University, Washington, DC 20007, USA
United States Food and Drug Administration, Silver Spring, MD 20993, USA
Author to whom correspondence should be addressed.
Toxins 2018, 10(7), 287;
Received: 4 June 2018 / Revised: 5 July 2018 / Accepted: 6 July 2018 / Published: 11 July 2018
(This article belongs to the Special Issue Uremia and Cardiovascular Disease)
Cardiovascular disease (CVD) remains a major cause of high morbidity and mortality in patients with chronic kidney disease (CKD). Numerous CVD risk factors in CKD patients have been described, but these do not fully explain the high pervasiveness of CVD or increased mortality rates in CKD patients. In CKD the loss of urinary excretory function results in the retention of various substances referred to as “uremic retention solutes”. Many of these molecules have been found to exert toxicity on virtually all organ systems of the human body, leading to the clinical syndrome of uremia. In recent years, an increasing body of evidence has been accumulated that suggests that uremic toxins may contribute to an increased cardiovascular disease (CVD) burden associated with CKD. This review examined the evidence from several clinical and experimental studies showing an association between uremic toxins and CVD. Special emphasis is addressed on emerging data linking gut microbiota with the production of uremic toxins and the development of CKD and CVD. The biological toxicity of some uremic toxins on the myocardium and the vasculature and their possible contribution to cardiovascular injury in uremia are also discussed. Finally, various therapeutic interventions that have been applied to effectively reduce uremic toxins in patients with CKD, including dietary modifications, use of prebiotics and/or probiotics, an oral intestinal sorbent that adsorbs uremic toxins and precursors, and innovative dialysis therapies targeting the protein-bound uremic toxins are also highlighted. Future studies are needed to determine whether these novel therapies to reduce or remove uremic toxins will reduce CVD and related cardiovascular events in the long-term in patients with chronic renal failure. View Full-Text
Keywords: microbiota; microbiome; uremic toxicities; p-cresyl sulfate; indoles; trimethylamine-oxide; uremic toxins; intestinal microbiota; prebiotics; probiotics; synbiotics; adsorbents microbiota; microbiome; uremic toxicities; p-cresyl sulfate; indoles; trimethylamine-oxide; uremic toxins; intestinal microbiota; prebiotics; probiotics; synbiotics; adsorbents
Show Figures

Figure 1

MDPI and ACS Style

Velasquez, M.T.; Centron, P.; Barrows, I.; Dwivedi, R.; Raj, D.S. Gut Microbiota and Cardiovascular Uremic Toxicities. Toxins 2018, 10, 287.

AMA Style

Velasquez MT, Centron P, Barrows I, Dwivedi R, Raj DS. Gut Microbiota and Cardiovascular Uremic Toxicities. Toxins. 2018; 10(7):287.

Chicago/Turabian Style

Velasquez, Manuel T., Patricia Centron, Ian Barrows, Rama Dwivedi, and Dominic S. Raj. 2018. "Gut Microbiota and Cardiovascular Uremic Toxicities" Toxins 10, no. 7: 287.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop